Systemic Mastocytosis (SM) Clinical Trials and Treatments

Systemic Mastocytosis results from clonal proliferation of mast cells due to activating mutations, most commonly KIT D816V, leading to accumulation of abnormal mast cells in bone marrow, lymphoid tissues, skin, and other organs. Mast cells produce numerous mediators including histamine, tryptase, heparin, and various cytokines that cause symptoms upon release. The disease is classified into several subtypes: indolent systemic mastocytosis (ISM), smoldering systemic mastocytosis (SSM), systemic mastocytosis with associated hematologic neoplasm (SM-AHN), aggressive systemic mastocytosis (ASM), and mast cell leukemia (MCL), with widely varying prognosis and management.

The most common symptoms of Systemic Mastocytosis include Flushing and itching, especially with triggers like heat or food, Abdominal pain, diarrhea, and malabsorption, Bone pain and osteoporosis, Anaphylactic reactions with throat tightness and hypotension, Headaches and cognitive difficulties, among others. Approximately 1 case per 10,000 to 20,000 people; can occur at any age but more common in adults. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Systemic Mastocytosis from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Research in Systemic Mastocytosis continues expanding treatment options for different subtypes and genetic profiles. Kinase inhibitors like midostaurin, already FDA-approved for advanced forms, are part of a growing arsenal of targeted therapies.

As of September 2026, Trial Friend's curated drug index does not include an FDA-approved treatment specific to Systemic Mastocytosis. The Treatments section of this page checks FDA drug labels live and lists any approved drug whose label names the condition, and the trials listed below cover the investigational options. The FDA is due to decide on Bezuclastinib by December 30, 2026; the FDA calendar page carries the outcome the day it lands.

Systemic Mastocytosis arises from acquired (somatic) genetic changes in the affected cells, commonly involving KIT, rather than from an inherited variant. Most cases carry a somatic activating KIT variant (usually D816V) in mast cells; additional somatic changes in TET2, SRSF2, ASXL1, RUNX1 or DNMT3A mark more aggressive disease. Approximately 1 case per 10,000 to 20,000 people; can occur at any age but more common in adults.

For Systemic Mastocytosis the genetic testing that matters is usually of the tumor or affected blood cells rather than inherited DNA, looking for KIT. Most cases carry a somatic activating KIT variant (usually D816V) in mast cells; additional somatic changes in TET2, SRSF2, ASXL1, RUNX1 or DNMT3A mark more aggressive disease.

Those results guide treatment choice and are often the entry requirement for targeted-therapy trials, so ask whether the biopsy was sent for molecular testing and request the report. The Genetic Testing section of this page lists laboratories in the NIH Genetic Testing Registry.

Eligibility for Systemic Mastocytosis clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Systemic Mastocytosis clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.